WASHINGTON (Reuters) – Canada-based Bausch Health Companies Inc has agreed to pay a $45 million penalty to settle charges of improper revenue recognition and misleading disclosures in Securities and Exchange Commission filings and earnings presentations, the SEC said on Friday.
Three former executives, including the chief executive officer of the company, formerly Valeant Pharmaceuticals, also agreed to pay penalties to settle charges against them, the SEC said.
(Reporting by Tim Ahmann; Writing by Mohammad Zargham)
